Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
32 hedge funds and large institutions have $16.5M invested in Sigilon Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
2,600% more call options, than puts
Call options by funds: $27K | Put options by funds: $1K
169% more capital invested
Capital invested by funds: $6.12M → $16.5M (+$10.4M)
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$173K |
| 2 |
Millennium Management
New York
|
+$37.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.7K |
| 4 |
Jane Street
New York
|
+$25.2K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$70.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$26.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$21K |
| 4 |
E
Ergoteles
New York
|
-$15.3K |
| 5 |
BlackRock
New York
|
-$10.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $8.25K | -$21 | -2 | -0.3% |
|
27
Barclays
London,
United Kingdom
| $2.18K | – | – | – |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| $1.19K | -$1.24K | -119 | -55% |
|
29
UBS Group
Zurich,
Switzerland
| $658 | +$561 | +54 | New |
|
30
Wells Fargo
San Francisco,
California
| $96 | – | – | – |
|
31
Osaic Holdings
Scottsdale,
Arizona
| $93 | – | – | – |
|
|
NECFA
32
New England Capital Financial Advisors
Meriden,
Connecticut
| $38 | – | – | – |
|
|
E
33
Ergoteles
New York
| – | -$15.3K | -3,374 | Closed |
|
|
34
Citadel Advisors
Miami,
Florida
| – | -$26.7K | -2,575 | Closed |
|
35
Simplex Trading
Chicago,
Illinois
| – | -$1.47K | -141 | Closed |
|
36
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$4 | -1 | Closed |
|
SGTX Hedge Fund Activity: Q1 2023 in Review
32 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q1 2023, worth a combined $16.5M — up 169% from $6.12M a quarter earlier.
Fund positioning in SGTX was balanced in Q1 2023: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $173K. The largest seller was Renaissance Technologies, cutting an estimated $70.6K.
- 32 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $16.5M of Sigilon Therapeutics, Inc. Common Stock stock for Q1 2023, up 169% quarter-over-quarter.
- 5 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of 0 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q1 2023 was Morgan Stanley, an estimated $173K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q1 2023 was Renaissance Technologies, an estimated $70.6K sold.
Based on aggregated 13F filings for Q1 2023.